Crinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-executive employees

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences


Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the Piper Sandler 35th Annual Healthcare Conference on November 30.

Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-executive employees

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2023 progress

Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees